1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 7,600 | 7,850 | 29.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.09. | WuXi XDC secures regulatory approval for Singapore site | 4 | Singapore Business Review | ||
| 21.09. | WuXi XDC Secures GMP Release for Singapore Manufacturing Site | 3 | Contract Pharma | ||
| WUXI XDC Aktie jetzt für 0€ handeln | |||||
| 18.09. | WUXI XDC (02268): INTERIM REPORT 2026 | - | HKEx | ||
| 17.09. | WuXi XDC to Out-License Proprietary Payload-Linker Technology Platform to Ona Therapeutics | 1 | Contract Pharma | ||
| 28.08. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 27.08. | WuXi XDC Cayman: Großaktionär plant Anteilsverkauf - Aktie gibt nach | 1 | Investing.com Deutsch | ||
| 25.08. | WuXi XDC H1 2026 slides: profit tops RMB 1bn, backlog hits $2bn | 5 | Investing.com | ||
| 25.08. | WuXi XDC: Gewinn im ersten Halbjahr 2026 übersteigt 1 Milliarde RMB - Aktie legt um 15 % zu | 1 | Investing.com Deutsch | ||
| 25.08. | WUXI XDC (02268): GRANT OF RESTRICTED SHARES UNDER THE 2024 SHARE SCHEME | - | HKEx | ||
| 25.08. | WuXi XDC Aktie steigt nach starken Halbjahresergebnissen um fast 12 % | 1 | Investing.com Deutsch | ||
| 24.08. | WuXi XDC Cayman Inc. Profit Climbs In H1 | 1 | RTTNews | ||
| 24.08. | WUXI XDC (02268): INSIDE INFORMATION 2026 INTERIM RESULTS PRESENTATION | - | HKEx | ||
| 24.08. | WUXI XDC (02268): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 2 | HKEx | ||
| 14.07. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 10.07. | WUXI XDC (02268): NOTICE OF BOARD MEETING | - | HKEx | ||
| 02.07. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 26.06. | WUXI XDC (02268): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026 | - | HKEx | ||
| 26.06. | WUXI XDC (02268): CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING ... | - | HKEx | ||
| 17.06. | WUXI XDC (02268): CONNECTED TRANSACTION ENTERING INTO OF PROCESS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT | 1 | HKEx | ||
| 01.06. | WUXI XDC (02268): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 26, 2026 | - | HKEx |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,050 | -0,11 % | Bye, bye Börse: Delisting: DAX-Aktie Qiagen wird wohl bald verschwinden | © Foto: Andreas Arnold/dpaDer Private-Equity-Riese EQT will Qiagen übernehmen. Experten trauen dem Angebot den Durchbruch zu. Der Diagnostik-Konzern dürfte anschließend von der Börse genommen werden.... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 288,62 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| DISC MEDICINE | 82,84 | 0,00 % | Disc Medicine Inc: Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update | Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis for CRL response; topline data expected in Q4 2026Launched Expanded... ► Artikel lesen | |
| BEAM THERAPEUTICS | 28,840 | 0,00 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 16,200 | 0,00 % | Summit Therapeutics: Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China | First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,235 | -0,12 % | 90% der Wirkstoffkandidaten scheitern: Wie Nvidia, Bristol Myers Squibb, Recursion und NeuroThera das größte Pharmaproblem angreifen | ||
| KINIKSA PHARMACEUTICALS | 97,48 | -0,08 % | Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales | ||
| KYMERA THERAPEUTICS | 122,55 | -0,04 % | Kymera Therapeutics: Brookline Capital hebt Kursziel nach Risikoreduzierung an | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 12,585 | +0,12 % | What's Going On with MoonLake Immunotherapeutics Stock on Thursday? | ||
| TANGO THERAPEUTICS | 22,510 | -0,09 % | Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside? | ||
| RAPPORT THERAPEUTICS | 24,190 | 0,00 % | Rapport Therapeutics bricht ein: Großvolumige Kapitalerhöhung mit hohem Abschlag belastet Kurs | ||
| 4D MOLECULAR THERAPEUTICS | 12,780 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für 4D Molecular Therapeutics | ||
| ARCUTIS BIOTHERAPEUTICS | 31,980 | +0,03 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints Rob Scott, MD to Board of Directors | ||
| COGENT BIOSCIENCES | 31,980 | 0,00 % | Stifel bekräftigt Kaufempfehlung für Cogent Biosciences nach ESMO-Daten | ||
| PRIME MEDICINE | 5,225 | -0,29 % | Prime Medicine, Inc.: Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease | -- Global, first-in-human study underway designed to evaluate safety, tolerability, and initial clinical efficacy of PM577a -- -- PM577a is designed as a one-time therapy to correct the H1069Q mutation... ► Artikel lesen |
Das Unternehmen WUXI XDC CAYMAN INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 7,600 Euro und damit -2,56 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu WUXI XDC CAYMAN INC finden Sie auf Wallstreet Online.